GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Enterprise Value

Venus Medtech (Hangzhou) (HKSE:02500) Enterprise Value : HK$2,527.4 Mil (As of May. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Venus Medtech (Hangzhou)'s Enterprise Value is HK$2,527.4 Mil. Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-735.7 Mil. Therefore, Venus Medtech (Hangzhou)'s EV-to-EBIT ratio for today is -3.44.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Venus Medtech (Hangzhou)'s Enterprise Value is HK$2,527.4 Mil. Venus Medtech (Hangzhou)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-599.2 Mil. Therefore, Venus Medtech (Hangzhou)'s EV-to-EBITDA ratio for today is -4.22.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Venus Medtech (Hangzhou)'s Enterprise Value is HK$2,527.4 Mil. Venus Medtech (Hangzhou)'s Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$537.5 Mil. Therefore, Venus Medtech (Hangzhou)'s EV-to-Revenue ratio for today is 4.70.


Venus Medtech (Hangzhou) Enterprise Value Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Enterprise Value Chart

Venus Medtech (Hangzhou) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 12,654.79 30,282.35 9,627.59 5,220.86 2,525.79

Venus Medtech (Hangzhou) Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,627.59 6,062.71 5,220.86 2,086.96 2,525.79

Competitive Comparison of Venus Medtech (Hangzhou)'s Enterprise Value

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Medtech (Hangzhou)'s Enterprise Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Enterprise Value distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Enterprise Value falls into.



Venus Medtech (Hangzhou) Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Venus Medtech (Hangzhou)'s Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Venus Medtech (Hangzhou)'s Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Medtech (Hangzhou)  (HKSE:02500) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Venus Medtech (Hangzhou)'s EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2527.429/-735.702
=-3.44

Venus Medtech (Hangzhou)'s current Enterprise Value is HK$2,527.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-735.7 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Venus Medtech (Hangzhou)'s EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=2527.429/-599.213
=-4.22

Venus Medtech (Hangzhou)'s current Enterprise Value is HK$2,527.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-599.2 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Venus Medtech (Hangzhou)'s EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2527.429/537.454
=4.70

Venus Medtech (Hangzhou)'s current Enterprise Value is HK$2,527.4 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$537.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Venus Medtech (Hangzhou) Enterprise Value Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Traded in Other Exchanges
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines